On February 3, 2025 Orum Therapeutics ("Orum" or the "Company") (KRX: 475830), a clinical-stage biotechnology company pioneering the field of degrader-antibody conjugates (DACs), reported the pricing of its initial public offering of 2,500,000 shares of common stock at a public offering price of KRW 20,000 per share (Press release, Orum Therapeutics, FEB 3, 2025, View Source [SID1234649999]). All of the shares are being offered by Orum Therapeutics. The shares are expected to begin trading on the Korean Securities Dealers Automated Quotations (KOSDAQ) on February 14, 2025, under the stock code KRX: 475830. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Orum, are expected to be approximately KRW 50 billion.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The offering is expected to close on February 5, 2025, subject to the satisfaction of customary closing conditions.

Korea Investment Securities acted as underwriter for the offering.

A registration statement relating to the offering has been filed with the Financial Supervisory Service and was declared effective on January 16, 2025. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, when available, may be obtained for free by visiting DART on the Financial Supervisory Service website at View Source Alternatively, copies of the final prospectus, when available, may be obtained from Korea Investment Securities, Attention: https://securities.koreainvestment.com, by telephone at +82-2-3276-5783, +82-2-3276-5783-4528, or by email at [email protected].

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Korean Securities and Exchange Act, as amended, and otherwise in accordance with applicable securities laws in any other jurisdiction.

On February 3, 2025 Olema Pharmaceuticals, Inc. ("Olema" or "Olema Oncology", Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, reported that management will participate in the following investor conferences (Press release, Olema Oncology, FEB 3, 2025, View Source [SID1234649998]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Oppenheimer 35th Annual Healthcare Life Sciences Conference
Date: Wednesday, February 12, 2025 at 9:20 a.m. ET
Format: Virtual Presentation

Citi’s 2025 Virtual Oncology Leadership Summit
Date: Thursday, February 20, 2025 at 10 a.m. ET
Format: Virtual Fireside Chat

Live webcasts of these presentations will be available in the Events and Presentations section of Olema’s investor relations website at ir.olema.com. The webcasts will be archived for at least 30 days.

On February 3, 2025 Kazia therapeutics presented its corporate presentation (Presentation, Kazia Therapeutics, FEB 3, 2025, View Source [SID1234649997]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

On February 3, 2025 Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, reported that management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, which is taking place virtually from February 11-12, 2025, to discuss the company’s pipeline, platform, and business strategy (Press release, Immuneering, FEB 3, 2025, View Source [SID1234649996]). Participating will be Ben Zeskind, Chief Executive Officer, and Brett Hall, Chief Scientific Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Format: Company Presentation and 1×1 Investor Meetings

Date/Time: February 12 from 2:40 – 3:10 pm ET in Track 2

The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

On February 3, 2025 Enveric Biosciences, Inc. (NASDAQ: ENVB) ("Enveric" or the "Company"), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, reported the closing of its previously announced public offering of an aggregate of 1,666,666 shares of its common stock (or common stock equivalents in lieu thereof), Series A warrants to purchase up to 1,666,666 shares of common stock and Series B warrants to purchase up to 1,666,666 shares of common stock, at a combined public offering price of $3.00 per share (or per common stock equivalent in lieu thereof) and accompanying warrants (Press release, Enveric Biosciences, FEB 3, 2025, View Source [SID1234649995]). The warrants have an exercise price of $3.00 per share and are exercisable immediately. The Series A warrants will expire five years from the date of issuance and the Series B warrants will expire eighteen months from the date of issuance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

H.C. Wainwright & Co. acted as the exclusive placement agent for the offering.

The gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses payable by the Company, were approximately $5 million. The Company intends to use the net proceeds from this offering for product development, working capital and general corporate purposes.

The securities described above were offered pursuant to a registration statement on Form S-1 (File No. 333-284277), which was declared effective by the Securities and Exchange Commission (the "SEC") on January 30, 2025. The offering was made only by means of a prospectus forming part of the effective registration statement relating to the offering. A final prospectus relating to the offering has been filed with the SEC. Electronic copies of the final prospectus may be obtained on the SEC’s website at View Source and may also be obtained by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at [email protected].

This press release shall not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.